Calistoga Pharmaceuticals (Seattle, WA) a clinical-stage small molecule company focused on isoform-selective phosphatidylinositol 3 kinase inhibitors for the treatment of cancer and inflammatory diseases, closed a $40M Series C financing. Participants include Quogue Capital, Alta Partners, Amgen Ventures, Frazier Healthcare, Three Arch Partners and Latterell Venture Partners.

Visterra (Cambridge, MA) a development-stage company focused virus-glycan docking to derive products for the prevention, treatment and diagnosis of influenza and other infectious diseases, closed a $6M Series A financing. Participants include Flagship Ventures, Lux Capital and Polaris Venture Partners.

Mirina (Seattle, WA) a development-stage biotechnology company focused on miRNA therapeutics for oncology and metabolic disorders, closed a $3.9M Series A financing, bringing the total round to $7.5M. Participants include Versant Ventures, Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital.

Coronado Biosciences (Seattle, WA) a clinical-stage biopharmaceutical oncology company focused on AML, NSCLC, leukemia, lymphoma, and prostate cancer. Participants were not identified.

Eucodis Bioscience (Vienna) a commercial-stage company focused on the development, customization, manufacture and marketing of industrial enzymes, closed a $2.7m Series B financing. Participants include Pontis Capital, Wiener Wachstumsfonds and Arax Capital Partners.

EndoGastric Solutions (Redmond, WA) a commercial-stage medical device company focused on endoluminal procedures for the treatment of upper gastrointestinal diseases, including gastroesophageal reflux disease (GERD) and other GI disorders, closed a $21.5M Series E financing. Participants have included Advanced Technology Ventures, Chicago Growth Partners, DeNovo Ventures, Foundation Medical Partners, MPM Capitaland Oakwood Medical Investors.

Note: 2009 [...]

Integrated Diagnostics (Seattle, WA) a development-stage diagnostics company focused on rapid biomarker validation and parallel organ-centric assays, closed a $30M Series A financing. Participants include Interwest Partners, The Wellcome Trust and Dievini Hopp Biotech Holding.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

EndoGastric Solutions (Redmond, WA) a commercial-stage medical device company focused on endoluminal procedures for the treatment of upper gastrointestinal diseases, including gastroesophageal reflux disease (GERD) and other GI disorders, closed a $21.5 Series E financing. Participants have included Advanced Technology Ventures, Chicago Growth Partners, DeNovo Ventures, Foundation Medical Partners, MPM Capital and Oakwood Medical Investors.
Note: [...]

Calypso Medical Technologies (Seattle, WA) a commercial-stage medical device company focused on implantable sensor electromagnetic transponders, to accurately and continuously pinpoint the location of tumors in real-time during radiation therapy delivery, closed a $50M Series E financing. Participants include Skyline Ventures, Frazier Healthcare Ventures, Bay City Capital and InterWest Partners.

ConforMIS (Burlington, MA) a commercial-stage medical device company focused on personalized resurfacing implants, osteoarthritis treatment and joint damage, closed a $50M Series D financing. Participants include Aeris Capital and previous investors.

NanoString Technologies (Seattle, WA) a commercial-stage developer of instrumentation and assays for multiplexed detection and quantification of gene expression, closed a $30M Series C financing. Participants include Clarus Ventures, OVP Venture Partners and Draper Fisher Jurvetson.

Pathway Medical Technologies (Kirkland, WA) development-stage medical company focused on peripheral-arterial disease, closed a $42.5M Series D financing. Participants include HLM Venture Partners, Latterell Venture Partners, Oxford Bioscience Partners, Forbion Capital Partners, Giza Venture Capital and WRF Capital.

MediQuest Therapeutics (Bothell, WA) a late-stage specialty pharmaceutical company focused on inflammatory and infectious diseases such as Raynaud’s, nail psoriasis and actinic keratosis, closed a $23M Series B financing. Participants were not named however, Series A participants included Novo Ventures, Janus, Integra Ventures and Masa Life Science Fund.